Mike Flanagan, PhD

Chief Scientific Officer at Avidity Biosciences

Speaker

W. Michael Flanagan, Chief Scientific Officer, joined Avidity Biosciences in January 2021. At Avidity, Dr. Flanagan leads Research and Manufacturing of antibody oligonucleotide conjugates (AOCs) for the treatment of rare muscle diseases including myotonic dystrophy type 1, Duchenne muscular dystrophy and facioscapulohumeral muscular dystrophy (FSHD). Dr. Flanagan has extensive experience developing multiple therapeutic modalities, including RNA therapeutics, antibody drug conjugates, and bispecific antibodies. Prior to joining Avidity, Dr. Flanagan served as Senior Director and Project Team Leader, Oncology and Immunology for Genentech, Inc., where he advanced programs through late-stage research to end of Phase 2 development. Prior to Genentech, he served in roles of increasing responsibility in the biology groups at Sunesis Pharmaceuticals, Inc., Gilead Sciences, Inc., and Merck & Co., Inc. where he was Senior Director of RNA Sciences. Dr. Flanagan received a B.S. in Genetics from the University of California at Davis, a Ph.D. in Biological Sciences from the University of California at Irvine and was an American Cancer Society postdoctoral fellow at the Howard Hughes Medical Institute, Stanford University.